ASCO 2023 | A*02:01-negative uveal melanoma as an unmet need

Sapna Patel, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on unmet needs in uveal melanoma, including the lack of treatment options for patients with HLA-A*02:01-negative patients. Whilst HLA-A*02:01-postive uveal melanoma can be treated with tebentafusp, there is no standard of care for patients with A*02:01-negative uveal melanoma. Tumor-infiltrating lymphocytes (TIL) manufactured with the TIL 3.0 method are a promising strategy for this group of patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.